Failure Patterns and Individualized Treatment Plans of Reirradiation for Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2024 Aug 2

PMID 39095403

Authors

Cheng Lin

Qiongjiao Lu

Yuebing Chen

Xiaoqiang Chen

Yiping Huang

Hangyan Zhong

Xiane Peng

Cairong Hu

Bijuan Chen

Shaojun Lin

Jingfeng Zong

Affiliations

Soon will be listed here.

Abstract

Re-irradiation with intensity-modulated radiotherapy (IMRT) remains the primary treatment modality for inoperable locally recurrent nasopharyngeal carcinoma (NPC). However, the rate of radiation-related late adverse effects is often substantially high. Therefore, we aimed to explore failure patterns and individualized treatment plans of re-irradiation for inoperable locally recurrent NPC. Ninety-seven patients who underwent IMRT were retrospectively analyzed. Sixty-two patients had clinical target volume of recurrence (rCTV) delineated, and thirty-five patients had only gross tumor volume of recurrence (rGTV) delineated. Twenty-nine patients developed second local failures after re-irradiation with IMRT (28 cases available). Among those patients, 64.3% (18/28) of patients and 35.7% (10/28) developed in-field or out-field, respectively. No statistical correlation was observed between target volume (rGTV or rCTV) and the local recurrence rate, local failure patterns, grade ≥ 3 toxicity, and survival. Multivariate analysis showed that recurrent T (rT) stage (HR 2.62, P = 0.019) and rGTV volume (HR 1.73, P = 0.037) were independent prognostic factors for overall survival (OS). Risk stratification based on rT stage and rGTV volume revealed that low risk group had a longer 3-year OS rate (66.7% vs. 23.4%), lower total grade ≥ 3 toxicity (P = 0.004), and lower re-radiation associated mortality rates (HR 0.45, P = 0.03) than high risk group. This study demonstrates that the delineation of rCTV may not be beneficial for re-irradiation using IMRT in locally recurrent NPC. Patients with low risk were most suitable for re-irradiation, with maximizing local salvage and minimizing radiation-related toxicities. More precise and individualized plans of re-irradiation are warranted.

References

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

Lin S, Pan J, Han L, Guo Q, Hu C, Zong J . Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014; 110(3):385-9. DOI: 10.1016/j.radonc.2014.01.011. View

Wong K, Hui E, Lo K, Lam W, Johnson D, Li L . Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021; 18(11):679-695. DOI: 10.1038/s41571-021-00524-x. View

Saraswathula A, London Jr N . Recurrent Nasopharyngeal Carcinoma and the Role of Surgery. J Neurol Surg Rep. 2023; 84(3):e68-e70. PMC: 10344595. DOI: 10.1055/s-0043-1770966. View

Chua M, Ng W, Lee A . Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncol. 2021; 22(6):e217. DOI: 10.1016/S1470-2045(21)00143-1. View

Yan W, Liu T, He M, Yi J, Tang L, Ou X . Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis. Radiother Oncol. 2023; 188:109903. DOI: 10.1016/j.radonc.2023.109903. View

You R, Liu Y, Xie Y, Lin C, Duan C, Chen D . Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023; 401(10380):917-927. DOI: 10.1016/S0140-6736(23)00269-6. View

Zong J, Liang Q, Lu Q, Liu Y, Xu H, Chen B . Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma. BMC Cancer. 2021; 21(1):1274. PMC: 8620547. DOI: 10.1186/s12885-021-08995-y. View

Ng W, Soong Y, Ahn Y, AlHussain H, Choi H, Corry J . International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2021; 110(3):682-695. DOI: 10.1016/j.ijrobp.2021.01.041. View

10.

Yang X, Ren H, Yu W, Zhang X, Sun Y, Shao Y . Analysis of Clinical Target Volume Delineation in Local-regional Failure of Nasopharyngeal Carcinoma after Intensity-modulated Radiotherapy. J Cancer. 2020; 11(7):1968-1975. PMC: 7052868. DOI: 10.7150/jca.39588. View

11.

Li Y, Tian Y, Tan S, Liu M, Kusumawidjaja G, Ong E . Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy. J Clin Oncol. 2018; 36(9):891-899. DOI: 10.1200/JCO.2017.75.5165. View

12.

Tian Y, Xiao W, Bai L, Liu X, Zhao C, Lu T . Impact of primary tumor volume and location on the prognosis of patients with locally recurrent nasopharyngeal carcinoma. Chin J Cancer. 2015; 34(6):247-53. PMC: 4593352. DOI: 10.1186/s40880-015-0019-5. View

13.

Yue Q, Zhang M, Chen Y, Zheng D, Chen Y, Feng M . Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: A meta-analysis. Oral Oncol. 2018; 81:81-88. DOI: 10.1016/j.oraloncology.2018.04.017. View

14.

Karam I, Huang S, McNiven A, Su J, Xu W, Waldron J . Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. Head Neck. 2015; 38 Suppl 1:E1102-9. DOI: 10.1002/hed.24166. View

15.

Kong L, Shen C, Hu C, Wang L, Lu J . Salvage Intensity-Modulated Radiation Therapy (IMRT) for Locally Recurrent Nasopharyngeal Cancer after Definitive IMRT: A Novel Scenario of the Modern Era. Sci Rep. 2016; 6:32883. PMC: 5018695. DOI: 10.1038/srep32883. View

16.

Chan O, Sze H, Lee M, Chan L, Chang A, Lee S . Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. Head Neck. 2016; 39(3):533-540. DOI: 10.1002/hed.24645. View

17.

Lee A, Ng W, Chan J, Corry J, Makitie A, Mendenhall W . Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019; 79:101890. DOI: 10.1016/j.ctrv.2019.101890. View

18.

Zhan Y, Fan S . Multiple Mechanisms Involving in Radioresistance of Nasopharyngeal Carcinoma. J Cancer. 2020; 11(14):4193-4204. PMC: 7196263. DOI: 10.7150/jca.39354. View

19.

Zhang L, Wang W, Hu J, Lu J, Kong L . RBE-weighted dose conversions for patients with recurrent nasopharyngeal carcinoma receiving carbon-ion radiotherapy from the local effect model to the microdosimetric kinetic model. Radiat Oncol. 2020; 15(1):277. PMC: 7731771. DOI: 10.1186/s13014-020-01723-z. View

20.

Dionisi F, Croci S, Giacomelli I, Cianchetti M, Caldara A, Bertolin M . Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. Acta Oncol. 2019; 58(9):1238-1245. DOI: 10.1080/0284186X.2019.1622772. View